No Data
InnoCare Pharma Limited's (HKG:9969) 26% Share Price Surge Not Quite Adding Up
Trending Industry Today: INNOCARE Leads Gains In Biotechnology Stocks
The Medical sector has frequently issued Bullish policies, leading to a significant increase in the Hang Seng Yinhua CSI Innovative Drugs Industry ETF, Hang Seng Biotechnology ETF, Hang Seng Medical Index ETF, and Hong Kong Stock Connect Medical ETF.
Innovative Drugs and Medical stocks in Hong Kong surged, with INNOCARE, SIMCERE PHARMA, and ASCENTAGE-B rising over 12%; Lepu Biopharma-B, CMS, CSPC PHARMA, INNOVENT BIO, and Hutchmed (China) increased by more than 7%.
INNOCARE (09969) has submitted an application for the market launch of its new generation pan-TRK inhibitor.
Zurletrectinib is a pan-TRK inhibitor developed independently by INNOCARE (09969).
Express News | InnoCare Announces the Acceptance of New Drug Application for Pan-Trk Inhibitor Zurletrectinib in China
[Brokerage Focus] Guoyuan Securities (Hong Kong): The impact of Pharmaceutical tariffs is limited, and the outlook for Innovative Drugs going abroad is bullish.
Jinwu Finance | Guoyuan (Hong Kong) released a Research Report indicating that the US Secretary of Commerce, Raimondo, recently stated that tariffs on pharmaceuticals would be imposed within 1 to 2 months. However, the Institutions believe that there is uncertainty regarding the imposition of pharmaceutical tariffs, and it is merely a disturbance to the pharmaceutical Industry, with no impact on the prospects for Innovative Drugs going abroad. First, Guoyuan (Hong Kong) points out that the imposition of pharmaceutical tariffs by the USA has been repeated multiple times recently, and there is uncertainty regarding whether tariffs will actually be imposed. Even if imposed, the impact on Hong Kong-listed pharmaceutical companies would be minimal. Pharmaceutical companies only have some Active Pharmaceutical Ingredients and a small number of generic drugs sold in the USA, and the imposition, even if it occurs, would only be a disturbance to the pharmaceutical Industry.
